$FRNM

$FRNM · Ale's World of Stocks · 2026-11-15

AI 摘要 · Ale's World of Stocks

对说话者而言,FRNM 属于中性、暂不买入的标的。其结肠癌血液检测已获 FDA 批准,肺癌检测获得突破性认定,并已有推广合作伙伴;但高销售增长并未减少亏损,亏损持平或恶化;美国结肠检测销售掌握在同时拥有竞争性检测的合作伙伴手中,这一利益冲突需持续关注,且行业进入门槛较低。他看好其长期潜力,但将 FRNM 排在略低于一家更高增长同行的位置(尽管 FRNM 最低买入价更高,若在两者中投入 1,000 美元,他会选择该同行),且不会很快买入,需要数年业绩验证。

他说的是几年内
《Google is Betting $1.2B on These 5 Crashing Stocks 🚨》
Ale's World of Stocks发布 2026-11-15 · 13 段内容

播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策

05:15/ —打开原视频

逐段跳播

13 段内容
5:158:45

在第二笔交易中,我们有一家全新的上市公司,大多数普通投资者可能都没听说过,至少目前还没有。它就是Freenome,一家专门利用人工智能进行癌症检测的公司,代码是FRNM。

in the second deal, we have a brand new public company , probably unheard of by most ordinary investors, at least not yet. It is Freenome, a company specializing in cancer detection using artificial intelligence, and its code is FRNM.

Google去年7月通过与一家特殊目的收购公司(SPAC)合并上市后,目前持有其约3000万美元的自有股份。查看股票走势图后,我们发现它经历了剧烈波动。在最近一次暴跌之后,其价格目前稳定在略低于首次公开募股(IPO)时的水平。

Google currently owns about $30 million of its own shares after going public last July through a merger with a special purpose acquisition company (SPAC). Upon reviewing the stock chart, we find that it has experienced sharp fluctuations.

After a recent crash, its price has now stabilized at a level slightly below its initial public offering (IPO) levels .

但这家公司有趣的地方在于,Freenome利用人工智能通过简单的常规血液检测来早期发现癌症。例如,想想结直肠癌筛查检测是如何进行的。目前大约有5000万到6000万45岁以上符合条件的美国人完全不做检查,主要是因为传统的结肠镜检查难以进行,需要大量准备,甚至要请一整天假,而粪便检测也不是愉快的体验。

But what makes this company interesting is that Freenome uses artificial intelligence to detect cancer early through a simple routine blood test. For example, consider how a colorectal cancer screening test works.

There are currently approximately 50 to 60 million eligible Americans over the age of 45 who completely avoid getting tested, mainly because traditional colonoscopies are difficult to perform, require a lot of preparation, and even take a whole day off work, and stool tests are not a pleasant experience either.

Freenome开创性的Simple Screen CRC检测为这个问题提供了解决方案,让医生只需使用少量血液样本,就能在常规年度体检中筛查结肠癌。

Freenome’s pioneering Simple Screen CRC test offers a solution to this problem, allowing doctors to screen for colon cancer during routine annual checkups using only a small blood sample .

该检测已于去年7月获得美国食品药品监督管理局的批准,并于9月底正式推出。更妙的是,Freenome没有试图从零开始建立庞大的销售团队,而是与医疗保健巨头Exact Laboratories合作,由后者负责在美国推广该检测,该公司已在2000多个临床站点拥有800名训练有素的代表订购检测试剂盒。

The test had already received approval from the US Food and Drug Administration last July, and was officially launched at the end of September. Even better, instead of trying to build a huge sales team from scratch, Freenome partnered with healthcare giant Exact Laboratories to manage the test rollout in the United States, which already has 800 trained delegates in more than 2,000 clinical sites ordering test kits.

通过这笔交易,Freenome已获得超过2.4亿美元的预付款,并且在达到某些里程碑时还可获得高达8.85亿美元的总利润,外加每售出一份检测的10%作为收入。

Through this deal, Freenome has already raised more than $240 million as an upfront payment, and can also earn up to $885 million in total profits when certain milestones are reached, plus 10% as revenue on every test sold.

此外,不仅仅是结肠癌;他们针对肺癌的血液检测去年8月获得了美国食品药品监督管理局的“突破性发现”认定,赋予他们销售这项检测以及针对多种癌症的其他检测套件的完整权利。

In addition, it's not just colon cancer; their blood test for lung cancer received a " breakthrough discovery" designation from the U.S. Food and Drug Administration last August, giving them full rights to market this test, as well as their other suite of tests for multiple types of cancer.

然而,仍有一些真实的风险让我至少暂时保持中性。首先,尽管销售额确实在高速度增长,但他们的亏损在某些年份仍然持平甚至更糟。

However, there are still some real risks that make me, at least for the time being, remain neutral. Firstly, although sales are indeed growing at high rates, their losses remain the same or even worse in some years.

其次,Freenome 把结肠癌检测在美国销售的全部控制权交给了 Exact,而 Exact 同时也拥有 Cologuard,这家制造商的名字叫 Exact Sciences。

如果 Exact 比 Freenome 更大力地推广自家检测产品,这就会造成潜在的利益冲突。

Second, Freenome handed over full control of the U.S. sales of the colon cancer test to Exact, which also owns Cologuard, the manufacturer that goes by the name Exact Sciences.

This creates a potential conflict of interest if Exact promotes its own test more aggressively than Freenome.

因此,这件事应当持续关注。最后,目前这个领域并不太让我兴奋。我相信它们有潜力,但这更像是一项长期投资,而且我看不到明显的市场进入壁垒。

Therefore, this matter should be monitored. Finally, this is not an area that excites me much at the moment. I believe they have potential, but it's more of a long-term investment, and I don't see major barriers to market entry.

因此,我更倾向于把它们排在比 obsidian 稍低的位置,我认为 obsidian 整体上具有更高的增长潜力。

Therefore, I prefer to classify them perhaps slightly lower than obsidian, which I see as having higher growth potential overall.

确实,Freedom 的最低价格更高,但如果让我在两只股票中选一只投入1000美元,我会选择 Obsidian,因为它的长期增长潜力更高。

It is true that Freedom has a higher minimum price, but if I were offered $1,000 of either stock, I would choose Obsidian for its higher long-term growth potential .

不过,我并不打算在短期内买入其中任何一只;我需要再观察它们几年的表现,才会把它们视为一项认真的投资。

However, I do not intend to buy either of them anytime soon; I need to see how they perform for several more years before considering them a serious investment.

跨洋听风